High-risk TP53 mutations predict poor primary treatment response of patients with head and neck squamous cell carcinoma.
Vito Carlo Alberto CaponioKhrystyna ZhurakivskaMarco MascittiLucrezia TogniFrancesca SpiritoNicola CirilloLorenzo Lo MuzioGiuseppe TroianoPublished in: Oral diseases (2023)
This study improves current evidence on the role of TP53 mutations in treatment response in HNSCC patients.